

## Reference List for Phase II study Workshop 2014

1. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. *Biometrics* 8:143-151, 1982.
2. Simon R, Wittes RE, Ellenberg SS: Randomized phase II clinical trials. *Cancer Treat Rep* 69:1375-1381, 1985.
3. Simon R: Optimal two-stage designs for phase II clinical trials. *Control Clin Trials* 10:1-10, 1989.
4. Thall PF, Simon R: Incorporating historical control data in planning phase II clinical trials. *Stat Med* 9:215-228, 1990.
5. Simon R, Thall PF, Ellenberg SS: New designs for the selection of treatments to be tested in randomized clinical trials. *Stat Med* 13:417-429, 1994.
6. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. *J Clin Oncol* 23:7199-7206, 2005.
- 7 Ratain MJ, Sargent DJ: Optimising the design of phase II oncology trials: The importance of randomisation. *Eur J Cancer* 45:275-280, 2009.
8. Seymour L, Ivy SP, Sargent D et al. The design of phase II clinical trials testing cancer therapeutics: Consensus recommendations from the clinical trial design task force of the National Cancer Institute Investigational Drug Steering Committee. *Clin Cancer Res.*16: 1764-1769, 2010.
9. Puztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. *Clin Cancer Res.* 13:6080–6086, 2007.
10. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. *Clin Cancer Res.* 15:1898-1905, 2009.
11. Mandrekar SJ, An MW, Sargent DJ. A review of phase II trial designs for initial marker validation. *Contemp Clin Trials.* 36:597-604, 2013.
12. Song JX. A two-stage patient enrichment adaptive design in phase II oncology trials. *Contemp Clin Trials.* 37(1): 148-154, 2014.
13. Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. *J Natl Cancer Inst.* 103:1093-1100, 2011.
14. Ratain MJ, Karrison TG. Testing the Wrong Hypothesis in Phase II Oncology Trials: There is a Better Alternative. *Clin Cancer Res.* 13:781-782, 2007.

15. Rubinstein L, LeBlanc M, Smith MA. More randomization in Phase II Trials: Necessary but not sufficient. *J Natl Cancer Inst.* 103: 1075-1077, 2011.
16. Sharma MR, Karrison TG, Jin Y, et al. Resampling phase III data to assess phase II trial designs and endpoints. *Clin Cancer Res.* 18: 2309-2315, 2012.
17. LeBlanc M, Tangen C. Choosing phase II endpoints and designs: evaluating the possibilities. *Clin Cancer Res.* 18: 2130-2132, 2012.
18. Rubinstein L, Crowley J, Ivy P et al. Randomized phase II designs. *Clin Cancer Res.* 15:1883-1890, 2009.
19. Dhani N, Tu D, Sargent DJ, et al. Alternate endpoints for screening phase II studies. *Clin Cancer Res.* 15:1873-1882, 2009.
20. Tang H, Foster NR, Grothey A et al. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. *J Clin Oncol.* 28:1936-1941, 2010.